Selank and Semax: The Nootropic Peptides Researchers Are Watching

What Are Selank and Semax?

These two peptides share a geographic origin and a delivery route, but their structures and primary research areas diverge meaningfully.

Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory tetrapeptide tuftsin, with a stabilizing Pro-Gly-Pro tripeptide added to the C-terminus. Tuftsin itself plays roles in phagocytic activity and immune regulation. By extending the tuftsin sequence, researchers created a more metabolically stable compound that crosses into the central nervous system more reliably.

Semax is a synthetic heptapeptide analog of ACTH(4-10), a fragment of adrenocorticotropic hormone. The modification converts the short hormonal fragment into a peptide with greater CNS activity and substantially longer half-life than the native ACTH fragment. Semax has been a registered pharmaceutical in Russia since 1994, where it is prescribed for ischemic stroke and transient ischemic attack. That registration represents the strongest regulatory legitimacy either peptide holds anywhere, though Russian regulatory standards differ from FDA standards.

Neither peptide is approved by the FDA. In the United States, both are sold exclusively as research chemicals. The FDA has flagged both compounds for limited human safety data, immunogenicity concerns, and risks related to peptide-related impurities.

Proposed Mechanisms: What Researchers Are Studying

### Selank: Enkephalins, Serotonin, and GABA

Selank's proposed anxiolytic properties are thought to operate through at least three overlapping pathways, though the human evidence for each remains preliminary.

The most discussed mechanism involves enkephalin regulation. Research suggests Selank may inhibit the enzymatic degradation of enkephalins, endogenous opioid peptides involved in mood, stress response, and pain modulation. By slowing their breakdown, synaptic enkephalin tone may increase, producing effects that differ mechanistically from benzodiazepines despite some overlapping behavioral outcomes in rodent models.

A second proposed pathway involves serotonin transport. Preclinical work in stress models has observed that Selank administration reduces expression of the serotonin transporter (SERT) in hippocampal tissue, which would functionally increase synaptic serotonin availability. Direct clinical confirmation in humans has not been replicated in Western-standard trials.

A third line of inquiry involves GABAergic signaling. A study published in Frontiers in Pharmacology (2017) demonstrated that Selank influences expression of GABA-A receptor subunit genes in cell models, providing a molecular basis for anxiolytic-like activity without direct receptor binding in the classical benzodiazepine sense.

Selank's tuftsin ancestry also suggests immunomodulatory properties, though these are not the primary focus of nootropic research.

### Semax: BDNF, TrkB, and Neuroprotection

Semax has a more concentrated body of mechanistic literature, particularly around brain-derived neurotrophic factor (BDNF). A landmark preclinical study published in Brain Research (Dolotov et al., 2006) demonstrated that Semax administration increases BDNF and TrkB receptor expression in the rat hippocampus. The hippocampus is central to learning and memory consolidation, making this an important target.

A 2024 review synthesizing rodent data found that repeated Semax administration consistently elevated BDNF and upregulated TrkB receptor density in the prefrontal cortex, a region associated with working memory and executive function. Nerve growth factor (NGF) modulation has also been reported in preclinical studies. A 2025 study demonstrated that Semax and a derivative reduced reactive oxygen species production associated with amyloid-beta/copper interactions, pointing toward a neuroprotective pathway independent of BDNF activity.

The Evidence Gap: Russian Research vs. Western Replication

This is where honest framing becomes critical.

The bulk of published human data on both peptides originates from Russian clinical groups, often published in Russian-language journals with limited accessibility outside the Eastern European academic ecosystem. A 2008 randomized trial involving 62 patients comparing Selank to the benzodiazepine medazepam in generalized anxiety reported comparable anxiolytic efficacy for Selank, without the sedation associated with benzodiazepines. This trial is frequently cited. It remains one of the few human trials available, and it has not been independently replicated in a Western-standard, double-blind, placebo-controlled format.

For Semax, the human data is more developed in the context of acute ischemic stroke, where the compound is prescribed in Russia. For cognitive enhancement in healthy individuals, the human evidence is substantially thinner.

Western researchers and regulators require independent replication, registered pre-specified primary outcomes, and rigorous blinding. By those standards, both Selank and Semax remain promising but inadequately studied in Western scientific literature.

Selank vs. Semax: A Side-by-Side Comparison

|---|---|---|

What to Track if You Are Working With a Provider

If you are under the care of a licensed provider who monitors research-grade peptide protocols, systematic data collection is one of the most valuable things you can do. Anecdotal impressions fade; longitudinal data does not. [MyProtocolStack](/auth/login?mode=signup) is built specifically for this kind of structured self-tracking alongside clinical oversight.

### Subjective Markers Worth Logging

### Objective Biomarkers to Discuss With Your Provider

Cortisol is a primary stress-axis marker and directly relevant to any compound studied in the context of stress modulation. Track it on the [biomarkers hub](/biomarkers).

HRV (Heart Rate Variability) is a non-invasive proxy for autonomic nervous system tone and is sensitive to both stress states and recovery. Wearables generate longitudinal HRV trends that bloodwork alone cannot.

Sleep architecture, particularly deep sleep and REM percentages, is worth tracking for compounds studied in the context of neuroplasticity and stress.

hs-CRP offers a window into systemic inflammation, which intersects with both immune modulation (Selank's tuftsin ancestry) and neuroprotection. See the [hs-CRP biomarker page](/biomarkers/hs-crp).

Testosterone is not a primary endpoint for these peptides, but general hormonal panel baselines are part of responsible protocol monitoring. The [total testosterone page](/biomarkers/total-testosterone) covers what to track.

For context on related peptides, the [epithalon](/peptides/epithalon) and [MOTS-c](/peptides/mots-c) pages cover compounds that share some of the longevity and neurological research interest, while [PT-141](/peptides/pt-141) illustrates how intranasal peptide delivery differs by compound class.

Honest Evidence Tier Summary

|---|---|---|

Frequently Asked Questions

What is the difference between Selank and Semax?

Selank is derived from the immune peptide tuftsin and is primarily studied for anxiolytic and mood-related properties, while Semax is derived from the ACTH 4-10 fragment of adrenocorticotropic hormone and is studied mainly for neuroprotection and cognitive function. Both are administered intranasally and were developed in Russia.

Are Selank and Semax FDA-approved?

No. Neither is FDA-approved in the United States. They are classified as research chemicals. Semax has been registered as a pharmaceutical drug in Russia since 1994 for stroke-related indications. Always discuss any peptide research with a qualified, licensed healthcare provider.

How are these peptides administered in research settings?

Both are administered intranasally. This route is used because these short peptides degrade rapidly in the gastrointestinal tract, and the nasal mucosa provides more direct access to cerebrospinal circulation. Administration protocols are a matter for licensed providers, not self-directed use.

What markers could someone track while exploring nootropic peptide research?

Researchers and clinicians often follow subjective markers (mood, sleep quality, cognitive clarity, stress perception) alongside objective biomarkers including cortisol, HRV, sleep architecture from wearables, and in some cases BDNF levels. Tracking these over time is exactly what platforms like MyProtocolStack are built for.

Is the human evidence for Selank and Semax strong?

The honest answer is no, not by Western standards. Most human data comes from Russian clinical publications, some of which lack the trial design standards required for FDA consideration. Preclinical rodent and cell studies are more numerous. Independent Western replication remains very limited. Researchers treat the existing evidence as preliminary.

Sources

1. Dolotov OV, et al. "Semax, an analog of ACTH(4-10), regulates BDNF and trkB expression in the rat hippocampus." Brain Research, 2006.

2. Pavlova TV, et al. "Efficacy and possible mechanisms of action of the peptide anxiolytic Selank in generalized anxiety disorders and neurasthenia." Zh Nevrol Psikhiatr, 2008.

3. Lebedeva IS, et al. "Effects of Semax on the Default Mode Network of the Brain." Bulletin of Experimental Biology and Medicine, 2018.

4. "GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission." Frontiers in Pharmacology, 2017.

5. "The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in an Animal Model of Alzheimer's Disease." 2025.

6. Kolomin T, et al. "Semax and selank: regulatory peptides with anxiolytic and nootropic activity." Review, 2024.

7. Biotechpeptides. "From Tuftsin to Selank: Exploring the Synthetic Heptapeptide." 2025.

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment. Selank and Semax are not FDA-approved compounds and are classified as research chemicals in the United States. Always consult a qualified, licensed healthcare professional before beginning, modifying, or discontinuing any peptide protocol or health intervention.*